Melatonin, a Powerful Hormone
Recent research suggests that high-dose melatonin may have a role in cancer treatment. Melatonin, a hormone produced naturally by the pineal gland, is known for regulating sleep-wake cycles. It is produced by the body in response to darkness but has many other important roles in the body.
Here are the Key Insights of High-Dose Melatonin for Cancer:
Antioxidant Properties:
Melatonin acts as a powerful antioxidant, neutralizing harmful free radicals that can contribute to cancer development and progression.1
Immune Support:
Melatonin for cancer stimulates immune function, potentially enhancing the body’s ability to combat cancer cells.2
Anti-Cancer Effects:
Studies indicate that high-dose melatonin may exert direct anti-cancer effects, inhibiting tumor growth and promoting cancer cell death.3
Synergy with Treatment:
Melatonin may enhance the effectiveness of chemotherapy and radiation therapy while reducing their side effects.4
Your naturopathic doctor can provide guidance on dosage, potential interactions, and its integration into a comprehensive cancer treatment strategy.
Melatonin for Adjunctive Cancer Therapy
NIHA physicians provide integrative, supportive and adjunctive cancer treatments which may enhance the body’s ability to fight cancer and help conventional cancer treatments work more effectively. Whereas conventional medicine will focus on treating the tumor, the integrative approach is patient-centered and supportive to the whole person while undergoing traditional treatment.
References:
1. Reiter, R. J., et al. (2017). Melatonin in the context of the ubiquitin–proteasome system: a well‐deserved TOSS? Journal of pineal research, 62(3), e12389.
2. Sainz, R. M., et al. (2019). Melatonin and cancer: current knowledge and future perspectives. Melatonin research, 2(2), 120-134.
3. Hill, S. M., et al. (2012). Melatonin: an inhibitor of breast cancer. Endocrine-related cancer, 19(3), R115-R133.
4. Dauchy, R. T., et al. (2009). Effect of melatonin administration on doxorubicin-induced cardiotoxicity. Toxicology and applied pharmacology, 238(1), 12-19.
